Novavax is no longer a struggling vaccine seller—it’s a cash-backed, Sanofi-powered royalty platform whose upside hinges on a single combination-shot clinical readout.
Overview
As of January 2026, Novavax is in a rebuilt identity phase: no longer attempting to be a full-stack pandemic-era manufacturer, it is repositioned as a partnership-led vaccine technology licensor monetizing its Matrix-M™ adjuvant and recombinant protein platform. The May 2024 Sanofi agreement is transformative—de-risking the balance sheet, outsourcing commercialization, and establishing a path to recurring, high-margin royalties and milestones. The near-term narrative is awkward: 2026 will show a sharp decline in recognized revenue ($185–205M ex-royalties) versus 2025’s >$1B framework, largely due to accounting roll-off of upfront amortization rather than a collapse in long-term economics. Investors must look through this “revenue valley” to the royalty ramp as Sanofi assumes full US/EU control and to the pivotal CIC Phase 3 readout expected mid-2026. NVAX trades near cash/enterprise value levels (market cap ~ $1.15B; EV ~ $540M after cash/debt), implying the market assigns minimal value to future Sanofi royalties and the pipeline. With ~$778M cash and reduced burn, downside is partially cushioned, while upside is tied to successful CIC data and Sanofi execution—creating an asymmetric, option-like risk/reward profile.